Resmedica Sp. z o.o.

Kielce 15 trials 6 recruiting

15 Registered trials

6 Currently recruiting

Organisation

Resmedica Sp. z o.o.

Location

Kielce, Poland

Identifier

ORG-100046497

Address

Ul. Romualda Mielczarskiego 105/3-4, 25-726, Poland

Departments

#5802
1902
2602
6002
N/A
NA
Poradnia Neurologiczna
Resmedica
unknown

Clinical trials at this site (15)

Search interface

Concentration of ofatumumab in the breast milk of lactating women with relapsing forms of multiple sclerosis Recruiting

2023-505283-11-00 Relapsing forms of Multiple Sclerosis (RMS) 6 2024-12-10
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with P… Recruiting

2024-514617-35-00 Progressive forms of Multiple Sclerosis 4 2021-12-20
Study of an On-Body Injection System for Home Use of Ocrelizumab in People with Multiple Sclerosis Recruiting

2025-523726-40-00 Multiple Sclerosis 5 2026-06-24
A Phase 2, Multicenter, Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Ublituximab Administered at Various Injection Site… Recruiting

2025-523757-33-00 multiple sclerosis 4 2026-05-07
A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has… Recruiting

2025-521636-10-00 Progressive Forms of Multiple Sclerosis (PMS) 4 2026-02-04
Evaluating safety, efficacy and pharmacokinetics of a modified regimen of ublituximab (ENHANCE) Recruiting

2024-519284-18-00 Relapsing multiple sclerosis 5 2025-06-18
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692… Ended

2024-512914-16-00 Relapsing-remitting Multiple Sclerosis 5 2025-09-12
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Ended

2024-514343-29-00 multiple sclerosis 5 2024-11-19
A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and S… Ended

2022-501622-37-00 Multiple Sclerosis 5 2024-01-16
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509345-12-00 Multiple Sclerosis 5 2022-06-22
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis Ended

2022-502618-95-00 Relapsing multiple sclerosis (RMS) 5 2020-11-24
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis Ended

2023-505980-36-00 Primary progressive multiple sclerosis (PPMS) 5 2019-09-19
An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended

2023-507906-15-00 Relapsing multiple sclerosis (RMS) 5 2019-01-30
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adult… Ended

2022-502552-31-00 Relapsing Forms of Multiple Sclerosis 4 2023-10-03
An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from fumarate-based RMS approv… Ended

2023-507493-41-00 relapsing multiple sclerosis (RMS) 5 2020-08-04